GenoMed Celebrates 6th Anniversary Of Dialysis Prevention Paper

Main Category: Urology / Nephrology
Article Date: 05 Sep 2008 - 5:00 PDT

email to a friend   printer friendly   opinions  

GenoMed® (OTC Pink Sheets GMED.PK), the Public Health Company™, announced that it is celebrating the sixth anniversary of the publication of its paper showing how to prevent 90% of kidney failure.

Diabetes and high blood pressure cause 90% of kidney failure. Sixty million Americans have high blood pressure and are at risk for kidney failure, and 20 million Americans have diabetes. Diabetes actually leads high blood pressure as the #1 cause of kidney failure.

Over 100,000 new patients go on the kidney machine (dialysis) each year. There are far too few kidney transplants for all these patients. There are currently over half a million patients on dialysis. Once on dialysis, life expectancy is quite limited - less than five years, on average.

GenoMed's paper shows that kidney failure can be reversed early on in the course of the disease, before a common marker of kidney failure, the serum creatinine, reaches 2. GenoMed's is still the only paper in the medical literature showing that it's possible to reverse chronic kidney disease in whites and blacks. Blacks go on dialysis 5 times more than whites. The company has a pending patent on its treatment, which uses already existing, generic drugs, but at novel doses.

Dr. David Moskowitz, GenoMed's CEO and the author of the paper, said, "It's too bad that our paper remains unknown. Perhaps we could have gotten more publicity if the two agencies which sponsored the critical research in my laboratory 15 years ago, the American Diabetes Association and the Missouri Kidney Program, had said something about the paper when it came out in 2002, or since. Or if the National Kidney Foundation, which actively screens patients for kidney failure, had mentioned that there's now a way to prevent kidney failure."

Continued Dr. Moskowitz, "Or if Medicare, which pays $25 billion a year for dialysis and transplantation, had shown the slightest interest in cutting its budget by 90% when I briefed the Medical Director in 2004. Or if academic nephrology divisions wanted to actually eliminate disease, as academics did 50 years ago. Or if the National Institutes of Health wanted to do something for taxpayers after all these years of huge budgets. The NIH actually has a National Kidney Disease Education Program which would be perfect for getting the word out to the 80 million Americans who need to know."

Dr. Moskowitz ended by saying, "We have a healthcare establishment that says it wants to cure diseases. It extracts an enormous amount of money from taxpayers. The overall healthcare budget in the US is over $2 trillion a year. Health insurance plans, by their own admission, refuse to spend a dime on preventing disease. By its collective silence and inaction, the healthcare system has shown me these past 6 years that what it really wants to do is keep common diseases around, and continue to make money from them. A dialysis patient brings in $100K a year. Healthcare needs to be completely overhauled in this country if taxpayers want to get their money's worth. And anybody who contributes money to a non-profit should think twice. Does that non-profit really want to put itself out of business in the next few years? If not, you're wasting your money, and, much more importantly, your time and your hope."

About GenoMed

In addition to reversing chronic kidney failure, GenoMed was recently awarded a patent for treating acute kidney failure without dialysis. GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5 years. Patients with early kidney failure are encouraged to contact Dr. Moskowitz at dwmoskowitz@genomed.com about joining GenoMed's Clinical Outcomes Improvement Program (COIP®). http://www.genomed.com

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

GenoMed

• Additional
• References
• Citations